Company intelligence / Profile preview

Cingulate Inc.

Kansas City, Kansas, United Statescingulate.com ↗

Ownership: Public · CING
Employees: ~13
Development stage: Phase 3

Overview

Cingulate Inc. is a clinical-stage biopharmaceutical company developing innovative treatments for ADHD and anxiety using its proprietary Precision Timed Release platform. Its lead candidate, CTx‑1301 (dexmethylphenidate), has reached Phase 3 trials for ADHD. Other pipeline assets include CTx‑1302 (dextroamphetamine) in Phase 1/2 and Phase 3 for pediatric ADHD, and CTx‑2103 (buspirone) targeting anxiety disorders. The company’s approach aims to enable once-daily dosing with improved efficacy and tolerability compared to existing therapies[1][3][4].

Therapeutic areas: Psychiatry
Modalities: Small molecules (dexmethylphenidate, dextroamphetamine, buspirone)[4]
Industry: Biotech

Drug pipeline

4 assets

CTx-1301

3 more assets in the full pipeline.

Request access →

Financials

Market cap: $69.9M
Total revenue: $0
Enterprise value: $47.8M

Beyond the preview

Go deeper on Cingulate Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cingulate Inc..

Explore the full profile